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Abstract
Background: Minichromosome maintenance proteins (MCM) are highly expressed in actively replicating cells. The need for
biological markers for cervical carcinoma and its precursor lesions is emerging. Our main aim was to determine the
immunohistochemical expression of MCM-2 in HIV-positive and -negative dysplastic cervical specimens.
Methods: Immunohistochemical analysis of MCM-2 was performed in a total of 352 cervical TMA specimens of normal
control, low-grade CIN, high-grade CIN and invasive tumor. 38 specimens were from HIV-positive women. A receiver
operating characteristic (ROC) curve was constructed to determine the best cutoff to diagnose high-grade CIN and invasive
cervical cancer.
Results: In the progression from normal epithelium to high-grade CIN and invasive tumor we found significant differences
in the MCM-2 expression (p,0.05). Based on the ROC curve of 80% with an area under the curve (AUC) of 0.78, expression of
MCM-2 to diagnose high-grade CIN and invasive tumor resulted in sensitivity of 81%, specificity of 66%, a positive predictive
value (PPV) of 86% and a negative predictive value (NPV) of 57%. HIV-positive cervices revealed a decreasing expression of
MCM-2 in both LGCIN and HGCIN compared with HIV-negative specimens (p,0.0001).
Conclusions: The present study suggests that immunohistochemical MCM-2 may not be a promising biomarker for
diagnosing high-grade CIN and invasive cancer.
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Introduction
A number of potential biomarkers for cervical screening have
been analyzed that appear to improve the detection of women at
greatest risk for developing cervical cancer [1]. The Minichromo-
some maintenance proteins (MCM) have emerged as promising
proliferation markers in several tumor types [2,3]. The MCM
protein family consists of 7 major isoforms (MCM2 - 8) that have
similar biochemical functions and are essential for DNA
replication. Dysregulated expression of MCM proteins is charac-
teristic in a variety of proliferative and malignant conditions,
leading to widespread expression [4].
Additional adjuncts are necessary to optimize the accuracy of
pathologic diagnosis of cervical neoplasia, considering the
interobserver and intraobserver variability for cervical dysplasia
in histology. Most studies have evaluated MCM immunohisto-
chemical expression based on the percentage of MCM staining
malignant cell. However, this is a controversial issue and no
standard definition for MCM expression have been developed [1].
Moreover, limited data of MCM-2 evaluation in cervical
specimens are available and none in the context of HIV-1
infection. Thus we aimed to evaluate the immunohistochemical
expression of MCM-2 in abnormal cervical epithelium in women
with and without HIV-1 co-infection to determine if MCM-2 is a
valid prognostic biomarker for cervical cancer.
Materials and Methods
A total of 352 Tissue Micro Array (TMA) specimens of
formalin-fixed, paraffin-embedded cervical tissues were immuno-
histochemically analyzed. Of these samples, 169 were obtained
from the archive files of the Department of Pathology from the
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e32936Fernandes Figueira Institute (IFF), Fiocruz, Rio de Janeiro, Brazil
between March 2009 to December 2009 and included 38 cervical
samples from HIV/HPV co-infected patients. The TMA blocks
were constructed as previously published [5], the size of the
punches were 1 to 1.5 mm diameter and there were two cores,
with full thickness of the cervical epithelium. Clinical information
were obtained from the record files. Another set of four TMA
slides was obtained from USBIOMAX-USA (CR 804, CIN 481,
BC 10021 and CR 2081), and all tested negative for HIV.
Additionally, 15 single slides of low grade CIN (CIN I) were
obtained from the Department of Pathology at Ohio State
University – USA. The cases were chosen at random from those
available in each diagnostic category. Specimens were identified
by final diagnosis on the histopathology report. The study was
approved by Oswaldo Cruz Foundation Institutional Ethics
Review-Board.
Immunohistochemistry analysis
Sections of 5 mm were cut on to silane-coated slides (Sigma, St.
Louis, MO, USA), and processed for immunohistochemistry, as
previously described [6]. We used mouse monoclonal primary
antibodies against MCM2 (BD ProEx
TM C, dilution 1:400).
Briefly, tissue slides were deparaffinized, and antigen retrieval was
carried out by treating the sections with Target Retrieval Solution,
pH 6.0 (S1699, DAKO, Copenhagen, Denmark). Primary
antibody (100 mL) was applied in a humidified chamber at 4uC
overnight. The LSAB system HRP (Dakocytomation, Carpinteria,
CA, USA) method was adapted for immune-labeling the
biotinylated link universal antibody and then the streptavidin-
HRP conjugate for 30 minutes. Slides were washed three times in
Tris pH 7.6 between each incubation step. Antibody binding was
visualized with Fast Red Chromogen (Sigma Chemical Co.,St.
Lois, MO, USA) for MCM-2. Finally, slides were counterstained
with hematoxylin, dehydrated and mounted in a resinous
mounting media (Merck, Darmstadt, Germany). Negative controls
were done for all tissues by omitting the primary antibody.
Immunohistochemical evaluation
The microscopic analysis of the slides was independently
performed by two investigators. Digitalized photographs were
taken with a Nikon COOLPIX Camera DP12, and the images
stored in a computer-based software program for documentation.
Quantitative results were expressed by % of stained cells/field as
previously published [6]. Only cells within cervical epithelium
were counted. All sections slides were assessed at 4006
magnification and separately evaluated by two observers (AFN)
with more than 10 years experience in immunohistochemistry and
(NO). The TMA were reviewed by an experienced molecular
pathologist (GN). Only nuclear staining was considered positive for
MCM-2. Results were compared with the HIV serostatus of the
patients.
Semiquantification of the stained cells on the layers of
cervical epithelium
Besides the quantification of total stained cells in the cervical
epithelium, described above, a semiquantification analysis was
done. Semiquantitative indication of the stained cells was obtained
by calculating a labeling index (LI), as previously published by
Freeman et al 1999 [4]. At least 200 nuclei were assessed per case.
Counts were done manually, a percentage of positively stained
nuclei out of the total number of nuclei were counted in
representative microscopic fields. Labeling index were determined
for three epithelial compartments. For each section the epithelial
thirds were defined by measuring the epithelial thickness and
dividing by 3: the basal and parabasal layer (1–3 layers); middle/
intermediate (around 8 layers) and superficial/upper layers (5–6
layers).
In situ hybridization and co-expression analyses
We performed HPV in situ hybridization on selected cases using
a previously published protocol [6]. The HPV in situ hybridization
was done for the purposes of co-expression analyses with MCM-2
in the same sections to be able to address the question as to
whether productive HPV infection was driving MCM-2 expres-
sion. The co-expression analysis was done with the Nuance system
as previously described [7]. in brief, the nuance system isolates the
blue and red spectra of the HPV DNA and MCM-2 protein,
respectively, converts it to fluorescent based signals and then
‘‘mixes’’ the two to determine if a given cell in making none, one,
or each of the targets.
Statistical analysis
Data analysis was carried out with SAS version 9.1 and R
2.11.1. The variables of MCM-2 expression are presented as
medians and interquartile ranges. Correlation by counting cells (%
stained/cells) was determined. Mann-Whitney U, Kruskal Wallis
and Dunn’s tests were applied to compare means of positive cells
in the epithelium of all cases (controls, low grade CIN, high grade
CIN and invasive cancer). The accuracy of MCM-2 expression to
diagnosis high grade CIN and invasive tumor was evaluated with
the use of ROC curve analyses according to standard procedures
[8,9]. A p value,0.05 was considered to indicate statistical
significance.
Results
Subjects samples and histopathological data
HIV seropositive subjects. Cervical TMA specimens from
38 HIV-infected women were analyzed, 18 were low grade CIN;
17 were high grade CIN and 3 invasive tumors. Patients’ mean age
was: 36 (SD 7.4); Median (IQR) 36.5 (31–42.7).
HIV seronegative subjects. Cervical TMA specimens from
314 women were included in this study. Patients mean age was:
44.3 (SD 6); Median (IQR) 49 (39–50) and consisted of 54 normal
controls; 24 low grade CIN (CIN I); 20 high grade CIN (CIN II/
III) and 216 invasive tumors. The invasive tumors consisted of 192
Squamous Cell Carcinomas (26 histological classified as grade 1;
166 were grade 2/3); and 24 adenocarcinomas).
Immunohistochemical data
In normal control cervices, MCM-2 expression was restricted to
the basal compartment; however MCM-2 expression increased in
the basal, middle and superficial layer (all compartments) in the
progression from low grade to high grade CIN. The mean
percentage of total MCM-2 immunopositivity cells in the cervical
epithelium are depicted on Table 1.
Interestingly, there was a marked and significant decrease in the
numbers of MCM-2 positive cells in the HIV-1 positive CIN
tissues compared to the HIV-1 negative CIN tissues
(p,0.0001).(table 2). Dunn’s test for multiple comparisons
revealed differences to normal controls compared to low-grade
CIN, high-grade CIN and invasive tumor. Low-grade CIN
compared to high-grade CIN and invasive tumor; and between
high-grade CIN and invasive tumor. All invasive tumors showed
high frequency of stained cell in most neoplastic cells. The
correlation of MCM-2 expression with the histological findings in
CIN lesions are shown on figure 1.
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we next addressed the question as to whether the MCM-2 positive
cells were primarily the cells with productive HPV infection.
However, analyzing the co-labeling for HPV 16 DNA in situ and
the MCM-2 by Nuance system, we found that the cells that
produce MCM-2 were not the same cells where HPV 16 DNA was
proliferating (figure 2). As is evident from the figure, in most cases
the MCM-2 positive cells lacked the cytologic features of
productive HPV infection (that is, the koilocyte), which was
reflected in a very poor correlation of HPV DNA detection by in
situ and co-expression of MCM-2 protein.
Semi quantitative analysis of MCM 2 labeling indices
To address the question whether there is difference in MCM-2
expression in the different layers of the cervical epithelium, we did
a semi quantitative counting analysis. In all lesions, MCM-2
staining was present in the parabasal and intermediate layer of the
epithelium. Positive expression on the superficial layer was present
in high grade CIN. On table 3 we can see the median labeling
indices found (percentage of stained cells) for MCM2 in Basal/
parabasal, Intermediate/middle and superficial/upper layers of
control, LGCIN (CIN I) and HGCIN (CIN II/III). A simplified
schematic representation of the control, LGCIN, HGCIN
expression patterns is depicted in Figure 3.
Evaluation of sensitivity and specificity of MCM-2 in
diagnosing high-grade CIN
Based on the receiver operating characteristic (ROC) curve of
80% with an area under the curve (AUC) of 0.78, expression of
MCM-2 to diagnose high-grade CIN and invasive tumor in the
HIV-1 negative CIN cases resulted in higher sensitivity (81%),
however moderate specificity (66%), positive predictive value
(PPV), (86%) and negative predictive value (NPV), (57%). The
results of ROC curve, sensitivity and specificity calculations are
depicted in Figure 4.
Discussion
In the present study we evaluated MCM-2 in normal and
abnormal cervical biopsies; we found an increasing percentage of
positive cells following the severity of CIN (p,0.0001), in
accordance with previous report [10]. MCM immunocytochem-
istry has great promise as a technique for cervical screening in
developing countries [10]. The search for biological markers for
predicting cervical carcinoma and its precursor lesions is a current
priority. Biomarkers that can accurately predict the future
development of disease are powerful screening tools that can
potentially lead to earlier detection and better prognosis for
patients with cervical precancerous lesions. MCMs are useful
markers of cell-cycle entry and are abundant in the nucleus
throughout the cell cycle and lost on cycle exit with rapid loss in
differentiating cells. Moreover, MCM-2 has been studied in a wide
range of human malignancies and has been associated with tumor
histopathological grade in several malignancies, including colon,
oral cavity, ovarian and urothelial carcinoma [1]. Significant
associations with MCM-5 and MCM-7 with histopathological
grade have been observed in cervical, ovarian and urothelial
tumors, suggesting that each member of MCM protein have
specific functions [1]. The majority of studies so far are restricted
to MCM-2, denoting that future research should be extended to
the other members of the MCM family. We found that MCM-2
stained cells were confined to the basal proliferate layer in the
normal cervix. However in the progression to CIN, higher
expression of this marker was found in all epithelial compartments,
Table 1. Crude table showing the % of stained cells in the
cervical epithelium.
MCM-2* Total %
Control
Mean (SD) 4.7 (1.6)
Median (IQR) 0.3 (0.0–0.6)
N5 4
Low grade CIN
Mean (SD) 32.9 (5.2)
Median (IQR) 26.9 (0.5–68.2)
N4 2
High grade CIN
Mean (SD) 31.6 (5.6)
Median (IQR) 0.7 (0.6–68.1)
N3 7
Invasive tumor
Mean (SD) 47.6 (2.2)
Median (IQR) 58.9 (0.9–76.0)
N2 1 9
P-valor ,0.0001
*Dunn’s test for multiple comparisons: revealed significant differences among
normal controls compared with low CIN, High grade CIN and invasive tumor;
and between low CIN compared to invasive tumor.
Moreover significant differences were found among Invasive tumor and control,
High grade CIN and control. Low grade CIN and control, invasive tumor and low
grade CIN and between invasive tumor and high grade CIN.
doi:10.1371/journal.pone.0032936.t001
Table 2. MCM-2 expression in HIV positive and negative
cervices.
Bio-marker MCM2
Manual
HIV- seronegative HIV seropositive P-valor
Control
Media (SD) 4.7 (1.6) - -
Median (IQR) 0.3 (0.0–0.6) -
N5 4 -
Low CIN*
Media (SD) 57.2 (4.9) 0.5 (0.5) ,0.0001
Median (IQR) 64.6 (40.8–74.6) 0.5 (0.4–0.6)
N2 4 1 8
High CIN
Media (SD) 58 (5.6) 0.6 (0.6) ,0.0001
Median (IQR) 67.2 (49.6–70.8) 0.6 (0.5–0.7)
N2 0 1 7
Invasive tumor
Media (SD) 47.5 (2.3) 54.1 (54.1) 0.7445
Median (IQR) 59.0 (0.9–76) 54.1 (52.4–55.9)
N 216 3
doi:10.1371/journal.pone.0032936.t002
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width of the epithelium in high grade CIN with the exception of
the cells that showed koilocytic changes and, as expected, high
copy HPV DNA. This suggests that productive HPV infection
which is typical especially of CIN 1 and CIN 2 lesions is associated
with the down-regulation of MCM-2 expression. The finding that
Figure 2. Co-expression analysis of MCM2 and HPV DNA in a CIN 1 lesion. Panel A shows the regular light microscopy view after in situ
hybridization for HPV 16 DNA (blue signal) followed by immunohistochemistry for MCM 2 (red signal). The image was then analyzed by the Nuance
system whereby the HPV 16 signal is fluorescent blue (panel B) and the MCM2 signal is fluorescent red (panel C). When the two latter images are
overlaid (panel D) it is evident that the cells expressing MCM2 do not have detectable HPV 16 DNA and vice-versa.
doi:10.1371/journal.pone.0032936.g002
Figure 1. Correlation of MCM2 expression with the histological findings in the uterine cervix. Panel A shows normal cervical epithelia
where MCM2 is restricted to the epithelial cells at the base of the mucosal surface. Panel B shows the MCM2 pattern in a CIN 1 lesion; note that the
protein in abundantly produced by the cells towards the base, but not in the cells towards the surface that show the koilocytic change classic for CIN
1. Panel C- shows the pattern of MCM2 expression in a CIN 3 lesion. Note the strong nuclear based signal present in the full thickness of dysplastic
epithelia. Panel D – shows the marked increased MCM2 expression in a invasive tumor lesion.
doi:10.1371/journal.pone.0032936.g001
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Basal/Parabasal layer % (range) Intermediate layer % (range) Superficial layer % (range)
Control .40 (40–60) .50 (50–60) 0
LG-CIN HIV-neg .80 (80–87) .40 (42–65) 0
LG-CIN HIV-pos .50 (50–83) .25 (25–50) 0
HG-CIN HIV-pos .80 (80–89) .85 (85–95) .30 (30–56)
HG-CIN HIV neg .90 (98–99) .90 (99–100) .25 (0–50) *
*2/20 HG-CIN specimens had no (0) immunopositivity cells.
doi:10.1371/journal.pone.0032936.t003
Figure 3. A simplified schematic representation of the different expression patterns in the three layers of the cervical epithelium. In
all lesions, MCM-2 staining was present in the parabasal and intermediate layer of the epithelium. Less expression was found on the control
specimens. Positive expression on the superficial layer was present in High grade CIN.
doi:10.1371/journal.pone.0032936.g003
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lesions is in agreement with one previous study [4].
To our knowledge no studies are available about MCM-2
expression in HIV abnormal cervices and few studies have
reported the use of these biomarkers in the pathology of HIV
positive anal dysplasia [11,12]. In our previous work [13] we
demonstrated significant altered expression of regulatory and cell
cycle proteins in the cervix from HIV-infected women, compared
to HIV non-infected cervices. Surprisingly, in this study we found
a marked decrease in the MCM-2 expression in the HIV positive
cervices in the CIN 1 and CIN2/3 lesions compared to HIV
negative, however the MCM-2 expression markedly increased in
the invasive tumor from women with HIV-confection. The basis
for this observation will require more study. It is established that
HIV-1 per se rarely infects the CIN cells [14]. However, as we and
others have shown, co-infection by HPV and HIV-1 results in
marked cytokine profile changes in the lamina propria of the
cervix which could translate into decreased MCM-2 expression in
the overlying CIN cells.
Interestingly, our co-labeling data revealed that MCM-2 stained
cells are mutually exclusive in a given lesion from cells which there
is detectable HPV16 DNA proliferation. This suggests that
productive HPV infection, as characterized by high copy HPV
DNA visualized by in situ hybridization, short-circuits the high
proliferation index of the cells migrating from the basal zone. One
may speculate that this may be advantageous to the spread of the
infectious HPV as it allows more viral DNA synthesis at the
expense of host cell DNA synthesis.
Most studies have evaluated MCM immunohistochemical
expression based on the percentage of MCM staining malignant
cells. However, this is a controversial issue and reports from prior
studies are quite variable [4,10,11]. There is a need for a standard
definition for MCM expression and which method provides the
best cut off points for considering a staining pattern as positive [1].
In this context it is necessary to define a standard criterion for
MCM expression in order to consider MCM as a diagnostic and
prognostic factor in routine clinico-pathological settings
In the present study, the accuracy of MCM-2 expression to
diagnosis high grade CIN and invasive tumors was evaluated with
the use of ROC curves. ROC analysis addresses the variance of
sensitivity and specificity and the AUC is the most commonly used
index of performance associated with ROC analysis [8].
According to standard procedures to achieve optimal sensitivity
and specificity and the cutoff of 80%, an AUC of 0.78 was
established. Our overall data resulted in relatively high sensitivity
(81%) and moderate specificity (66%), PPV (86%) and NPV
(57%), to diagnose high-grade CIN and invasive tumors. The
AUC can be interpreted as the average sensitivity over the entire
range of possible sensitivities [9]. One previous report found that
increasing the positive cutpoint for one specific marker increased
its specificity and accuracy for HGCIN [15].
There are several scales for AUC value interpretation, but in
general, ROC curves with an AUC #0.75 are not clinically useful
[8,9]. Therefore the AUC of 0.78 found on the present study
suggests that MCM-2 is a borderline biomarker in diagnosing high
grade cervical dysplasia and invasive tumors. In the present study
we performed two different counting cells analysis. Our semi-
quantification analysis of MCM-2 labeling index in the three
epithelium layers, did not reveal immunoreactive stained cells for
control as well for LGCIN in the superficial layer, however on
HGCIN, positive stained cells was seen (range 0–56), in both HIV
positive and negative cervices suggesting that MCM-2 probably
may have a role to distinguish LG-CIN from HG-CIN. However
more CIN specimens should be evaluated to confirm MCM2 as a
useful adjunct tool in distinguishing LG-CIN from HGCIN. The
crude total epithelium counting cell analysis found that our study
differ from others [10,11,16] that demonstrated MCM as a useful
biomarker for dysplasia and malignancy.
Figure 4. Receiver operating characteristic curve (ROC) for the overall performance of MCM-2 to predict high-grade CIN and
invasive tumor.
doi:10.1371/journal.pone.0032936.g004
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specificity of MCM-2. Neither PPV or NPV were provided, nor
any ROC curves to establish the best cut point. Furthermore it is
important to note that ROC performance may change when the
diagnostic test is applied in different clinical situations or under
different phases of test development [8]. In fact it will be rare for a
diagnostic test to have both 100% specificity and sensitivity. One
recent review concluded that there is no one biomarker which can
predict the potential to progress of a particular cervical lesion,
emphasizing that a combination of markers is more useful than a
single marker [17]. A limitation of our study was the relatively
small number of HIV positive samples, limiting subgroup analyses
and resulting in wide confidence estimates. Given this limitation,
our results should be viewed as hypothesis generating. Further
research is warranted to evaluate the potential role of MCM-2 as
diagnostic biomarker for CIN. In sum, our data suggests that
MCM2 may not be a useful indicator of CIN in general or invasive
cervical cancer because: 1) it has a relatively low specificity (66%)
plus NPV (57%) and 2) the expression of MCM2 can be markedly
influenced by non-HPV related factors, such as co-existent HIV-1
infection as shown in this.
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